Safety and Efficacy of PRG-2302 for Refractory or Relapsed B-cell Acute Lymphoblastic Leukemia Disease.

Trial Details

NCT ID

NCT06659653

Phase

EARLY_PHASE1

Sponsor

Tan Jie

Status

RECRUITING

Cancer Type

Leukemia

Interventions

• PRG2302

Locations (sample)

• Jinzhou, Hubei, China

Key Eligibility Criteria

• Age ≥18 years old, not over 70 years old (including 70 years old);
• Meet the following diagnostic criteria for recurrent or refractory B-ALL:
• A clear diagnosis of B-cell acute lymphoblastic leukemia with any of the following conditions Patients:
• recurrent: recurrence within 12 months after the first remission after standard treatment;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.